EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Randomisierte kontrollierte Studie

Inter-institutional heterogeneity in high-volume esophageal cancer centers: an ancillary study of JCOG1109 (JCOG2308A)

Ryosuke Kita, Ryunosuke Machida, Haruhiko Fukuda, Ken Kato, Yoshinori Ito, Hiroyuki Daiko, Koshiro Ishiyama, Hiroki Hara, Masato Nishida, Kazuo Koyanagi, Tetsuya Abe, Takeo Fujita und 7 weitere

Esophagus · 2026-10 · 23 (4) · 755-762

DOI: 10.1007/s10388-026-01229-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Esophagus, online erschienen am 30.06.2026. Verfasst von Ryosuke Kita und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-Ku, Kyoto, 606-8507, Japan. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Hospitals, High-Volume. Die Arbeit nennt 30 Literaturangaben. Gefördert von: National Cancer Center Research and Development Fund, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multimodal esophageal cancer treatment carries substantial perioperative risks. Although centralization has improved outcomes, variability may persist even among high-volume centers. This study aimed to evaluate inter-institutional heterogeneity in perioperative and survival outcomes using data from JCOG1109.

Methods

JCOG1109, a phase III multicenter trial, compared neoadjuvant cisplatin plus 5-fluorouracil (CF); docetaxel, cisplatin, and 5-fluorouracil (DCF); and cisplatin and 5-fluorouracil combined with radiotherapy (CF-RT) for stage IB–III esophageal squamous cell carcinoma. Individual patient data and institutional survey results were analyzed. Mixed-effects models with random intercepts and slopes, incorporating institutions as random effects, were applied to quantify heterogeneity in DCF and CF-RT’s treatment effects on postoperative complications, progression-free survival (PFS), and overall survival (OS), separated from baseline institutional risks in the CF arm.

Results

From 44 institutions, 580 patients were eligible and 546 underwent surgery. PFS treatment effect variance was smaller than baseline risk variability (CF: 0.062, standard deviation [SD]: 0.069; DCF: 0.044, SD: 0.053; CF-RT: 0.051, SD: 0.057), whereas OS variance exceeded baseline risk (CF: 0.058, SD: 0.068; DCF: 0.080, SD: 0.094; CF-RT: 0.072, SD: 0.079). Complication variance was lower in both experimental arms (CF: 0.342, SD: 0.432; DCF: 0.111, SD: 0.168; CF-RT: 0.190, SD: 0.326), although it was greater in the CF-RT arm than in the DCF arm.

Conclusions

Multimodal treatment was delivered with high consistency across specialized centers, as reflected by minimal heterogeneity in PFS. In contrast, moderate heterogeneity in OS indicated institutional influences, particularly post-recurrence management, which should be considered in trial designs and clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaHospitals, High-VolumeAgedFemaleHumansMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinCombined Modality TherapyDocetaxelFluorouracilNeoadjuvant TherapyNeoplasm StagingPostoperative ComplicationsProgression-Free SurvivalTreatment Effect Heterogeneity

Stichwörter der Autor:innen

Esophageal cancerHeterogeneityInter-institutional variationNeoadjuvant chemoradiotherapyNeoadjuvant chemotherapySquamous cell carcinoma

Substanzen

CisplatinDocetaxelFluorouracil

Autor:innen und Institutionen

  • Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-Ku, Kyoto, 606-8507, Japan.
  • Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Radiation Oncology, Showa Medical University School of Medicine, Tokyo, Japan.
  • Department of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.

Förderung

  • National Cancer Center Research and Development Fund
  • Japan Agency for Medical Research and Development

Zitieren

APA

Kita, R., Machida, R., Fukuda, H., Kato, K., Ito, Y., Daiko, H., Ishiyama, K., Hara, H., Nishida, M., Koyanagi, K., Abe, T., Fujita, T., Bamba, T., Tsushima, T., Sasaki, K., Tsunoda, S., Hida, K., Obama, K., & Takeuchi, H. (2026). Inter-institutional heterogeneity in high-volume esophageal cancer centers: an ancillary study of JCOG1109 (JCOG2308A). Esophagus, 23(4), 755-762. https://doi.org/10.1007/s10388-026-01229-9

Vancouver

Kita R, Machida R, Fukuda H, Kato K, Ito Y, Daiko H, et al. Inter-institutional heterogeneity in high-volume esophageal cancer centers: an ancillary study of JCOG1109 (JCOG2308A). Esophagus. 2026;23(4):755-762. doi:10.1007/s10388-026-01229-9

BibTeX
@article{Kita2026,
  author = {Kita, Ryosuke and Machida, Ryunosuke and Fukuda, Haruhiko and Kato, Ken and Ito, Yoshinori and Daiko, Hiroyuki and Ishiyama, Koshiro and Hara, Hiroki and Nishida, Masato and Koyanagi, Kazuo and Abe, Tetsuya and Fujita, Takeo and Bamba, Takeo and Tsushima, Takahiro and Sasaki, Keita and Tsunoda, Shigeru and Hida, Koya and Obama, Kazutaka and Takeuchi, Hiroya},
  title = {Inter-institutional heterogeneity in high-volume esophageal cancer centers: an ancillary study of JCOG1109 (JCOG2308A)},
  journal = {Esophagus},
  year = {2026},
  volume = {23},
  number = {4},
  pages = {755--762},
  doi = {10.1007/s10388-026-01229-9}
}
Kostenlos starten →